TR200100163T2 - Güçlendirilmiş farmakokinetik özelliklere sahip hibrid polipeptidler - Google Patents
Güçlendirilmiş farmakokinetik özelliklere sahip hibrid polipeptidlerInfo
- Publication number
- TR200100163T2 TR200100163T2 TR2001/00163T TR200100163T TR200100163T2 TR 200100163 T2 TR200100163 T2 TR 200100163T2 TR 2001/00163 T TR2001/00163 T TR 2001/00163T TR 200100163 T TR200100163 T TR 200100163T TR 200100163 T2 TR200100163 T2 TR 200100163T2
- Authority
- TR
- Turkey
- Prior art keywords
- pharmacokinetic properties
- core polypeptide
- hybrid polypeptides
- peptide sequences
- core
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 11
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 239000003623 enhancer Substances 0.000 abstract 3
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Bu bulus, orijinal olarak çesitli retrovirütik zarf (gp41) protein dizilerinden elde edilmis ve baglandiklari herhangi bir nüve polipeptidin farmakokinetik özelliklerini artiran, güçlendirici peptid dizileri ile ilgilidir. Bu bulus, bir nüve polipeptide bagli halde güçlendirici peptid dizilerini ihtiva eden hibrid polipeptidlerin, artirilmis yari ömür gibi güçlendirilmis farmakokinetik özelliklere sahip olduklarinin kesfedilmesine dayanir. Bu bulus ayrica, bir nüve polipeptidine güçlendirici peptid dizileri baglamak suretiyle, herhangi bir nüve polipeptidin farmakokinetik özelliklerini artirmaya mahsus yöntemlerle de ilgilidir. Bu bulusun uygulanmasinda kullanilacak nüve polipeptidler arasinda, örnegin bir terapötik veya profilaktik madde olarak kullanilabilecek, farmakolojik açidan yararli herhangi bir peptid bulunabilir.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/082,279 US6258782B1 (en) | 1998-05-20 | 1998-05-20 | Hybrid polypeptides with enhanced pharmacokinetic properties |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200100163T2 true TR200100163T2 (tr) | 2001-06-21 |
Family
ID=22170199
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/00163T TR200100163T2 (tr) | 1998-05-20 | 1999-05-20 | Güçlendirilmiş farmakokinetik özelliklere sahip hibrid polipeptidler |
Country Status (22)
Country | Link |
---|---|
US (3) | US6258782B1 (tr) |
EP (1) | EP1079846A4 (tr) |
JP (1) | JP2002515449A (tr) |
KR (1) | KR100742789B1 (tr) |
CN (1) | CN1205995C (tr) |
AU (1) | AU766995C (tr) |
BR (1) | BR9910626A (tr) |
CA (1) | CA2332338A1 (tr) |
HK (1) | HK1039747A1 (tr) |
HR (1) | HRP20000789A2 (tr) |
HU (1) | HUP0101826A3 (tr) |
ID (1) | ID29141A (tr) |
IL (2) | IL139702A0 (tr) |
MX (1) | MXPA00011314A (tr) |
NO (1) | NO20005836L (tr) |
NZ (1) | NZ508352A (tr) |
PL (1) | PL344342A1 (tr) |
RU (1) | RU2236865C2 (tr) |
TR (1) | TR200100163T2 (tr) |
WO (1) | WO1999059615A1 (tr) |
YU (1) | YU71800A (tr) |
ZA (1) | ZA200006642B (tr) |
Families Citing this family (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847452B1 (en) * | 1995-06-07 | 2009-04-01 | Progenics Pharmaceuticals, Inc. | Monoclonal antibody for inhibiting hiv-1 envelope glycoprotein mediated membrane fusion |
US7118859B2 (en) * | 1996-01-17 | 2006-10-10 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
US6344545B1 (en) * | 1996-06-14 | 2002-02-05 | Progenics Pharmaceuticals, Inc. | Method for preventing HIV-1 infection of CD4+ cells |
US7858298B1 (en) | 1996-04-01 | 2010-12-28 | Progenics Pharmaceuticals Inc. | Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists |
US20040086528A1 (en) * | 1996-06-14 | 2004-05-06 | Progenics Pharmaceuticals, Inc. | Uses of a chemokine receptor for inhibiting HIV-1 infection |
US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6656906B1 (en) * | 1998-05-20 | 2003-12-02 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US20040228869A1 (en) * | 1998-12-16 | 2004-11-18 | Progenics Pharmaceuticals, Inc. | Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto |
US20080015348A1 (en) * | 1998-12-16 | 2008-01-17 | Progenics Pharmaceuticals, Inc. | Nucleic acids encoding polypeptides of anti-CCR5 antibodies |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
EP2110381A1 (en) * | 1999-05-17 | 2009-10-21 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors of viral infection |
US6469136B1 (en) * | 1999-07-07 | 2002-10-22 | Trimeris, Inc. | Methods and composition for peptide synthesis |
US6277974B1 (en) | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US6623741B1 (en) * | 2000-02-29 | 2003-09-23 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission |
US6528308B1 (en) | 2000-03-16 | 2003-03-04 | Duke University | Suppressor of HIV replication and transcription |
US7138119B2 (en) * | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
KR100447943B1 (ko) * | 2000-11-06 | 2004-09-08 | 한국과학기술연구원 | Hiv의 감염 억제 펩타이드 |
US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
EP1752469B1 (en) * | 2001-05-31 | 2008-10-29 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors for HIV infection |
EP1390399B1 (en) | 2001-05-31 | 2005-05-11 | Conjuchem, Inc. | Long lasting fusion peptide inhibitors for hiv infection |
EP1479691B1 (en) * | 2001-05-31 | 2006-11-15 | ConjuChem Biotechnologies Inc. | Long lasting fusion peptide inhibitors for HIV infection |
US7160726B2 (en) * | 2001-06-07 | 2007-01-09 | Skin Medica, Inc. | Compositions comprising conditioned cell culture media and uses thereof |
ES2525317T3 (es) | 2001-06-15 | 2014-12-22 | F. Hoffmann-La Roche Ag | Producción recombinante de inhibidores de la fusión antivirales peptídicos |
US20070031440A1 (en) * | 2001-08-30 | 2007-02-08 | Prior Christopher P | Modified transferin-antibody fusion proteins |
EP1427750B1 (en) * | 2001-08-30 | 2010-12-08 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
FR2832715A1 (fr) * | 2001-11-29 | 2003-05-30 | Hippocampe | Polypeptides inhibiteurs de l'infectivite des virus de l'immunodeficience humaine |
US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
AU2003244516A1 (en) * | 2002-02-07 | 2003-09-02 | Novozymes Delta Limited | Hiv inhibiting proteins |
JP2006508631A (ja) | 2002-02-22 | 2006-03-16 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | 抗ccr5抗体 |
US7122185B2 (en) * | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
BR0303362A (pt) * | 2002-03-06 | 2005-07-19 | Univ Arizona State | Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal |
BR0312841A (pt) * | 2002-07-24 | 2005-12-06 | Hoffmann La Roche | Polipeptìdeo t1249 peguilado |
US20060130158A1 (en) * | 2002-08-30 | 2006-06-15 | Turner Andrew J | Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
AU2003275116A1 (en) * | 2002-09-24 | 2004-04-19 | Frontier Biotechnologies Co., Ltd | Peptide derivative fusion inhibitors of hiv infection |
US7045552B2 (en) * | 2002-09-27 | 2006-05-16 | Trimeris, Inc. | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy |
US7556813B2 (en) * | 2002-09-27 | 2009-07-07 | Trimeris, Inc. | Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides |
US20040076637A1 (en) * | 2002-09-27 | 2004-04-22 | Delmedico Mary Kay | HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus |
US7420037B2 (en) * | 2003-02-13 | 2008-09-02 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
CN1798770B (zh) * | 2003-04-04 | 2010-06-09 | 洛桑大学 | 用于治疗癌症的多聚肽体 |
US7309491B2 (en) * | 2003-04-11 | 2007-12-18 | Antigenics Inc. | Heat shock protein-based vaccines and immunotherapies |
ATE508139T1 (de) * | 2003-04-11 | 2011-05-15 | Pasteur Institut | Synthetische peptid-hiv-vakzine: das cbd-epitop als effizientes immunogen zur induktion hiv- neutralisierender antikörper |
US7379700B2 (en) * | 2003-05-06 | 2008-05-27 | Canon Kabushiki Kaisha | Image reading apparatus with rotatable internal and external guides |
WO2004106364A1 (en) * | 2003-08-05 | 2004-12-09 | Cornell Research Foundation, Inc. | Stabilizing peptides and their use in the preparation of stabilized hiv inhibitors |
US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
EP1663278A4 (en) * | 2003-08-28 | 2009-07-29 | Biorexis Pharmaceutical Corp | EPO MIMETIC PEPTIDES AND FUSION PROTEINS |
AU2004308952A1 (en) | 2003-12-23 | 2005-07-14 | Centocor, Inc. | Anti-retroviral agents, compositions, methods and uses |
CN1901931A (zh) * | 2004-01-07 | 2007-01-24 | 特里梅里斯公司 | HIV gp41 HR2-来源的合成肽,及其在抑制人类免疫缺陷性病毒传递的治疗中的用途 |
CA2562266A1 (en) * | 2004-04-08 | 2005-10-20 | Jadolabs Gmbh | Tripartite conjugates containing a structure interacting with cell membrane rafts and their use |
WO2005108418A1 (en) * | 2004-05-06 | 2005-11-17 | Conjuchem Biotechnologies Inc. | Compounds for specific viral target |
GB0422439D0 (en) * | 2004-10-08 | 2004-11-10 | European Molecular Biology Lab Embl | Inhibitors of infection |
US20070041943A1 (en) * | 2004-12-29 | 2007-02-22 | Children's Hospital Research | Expression of virus entry inhibitors and recombinant AAV thereof |
AU2006272750B2 (en) * | 2005-07-22 | 2011-09-29 | Cytodyn, Inc. | Methods for reducing viral load in HIV-1-infected patients |
TW200722436A (en) * | 2005-10-21 | 2007-06-16 | Hoffmann La Roche | A peptide-immunoglobulin-conjugate |
EP1989220B1 (en) | 2006-02-02 | 2011-12-14 | Trimeris, Inc. | Hiv fusion inhibitor peptides with improved biological properties |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
CN101088557A (zh) | 2006-06-12 | 2007-12-19 | 天津市扶素生物技术有限公司 | 用于预防或治疗hiv感染的药用组合物及其应用 |
CA2658654A1 (en) | 2006-07-24 | 2008-01-31 | Biorexis Pharmaceutical Corporation | Exendin fusion proteins |
TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
WO2008019817A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against ccr5 and an antifusogenic peptide |
ES2535358T3 (es) | 2006-12-12 | 2015-05-08 | Biorexis Pharmaceutical Corporation | Bibliotecas de proteínas de fusión de transferrina |
US20090088378A1 (en) * | 2007-01-12 | 2009-04-02 | Omar Quraishi | Long lasting inhibitors of viral infection |
US20090143288A1 (en) * | 2007-03-13 | 2009-06-04 | Roche Palo Alto Llc | Peptide-complement conjugates |
US20090068243A1 (en) * | 2007-04-03 | 2009-03-12 | Brian Bray | Novel formulations for delivery of antiviral peptide therapeutics |
CN101687911A (zh) * | 2007-05-16 | 2010-03-31 | 康久化学生物技术公司 | 抗病毒肽的半胱磺酸衍生物 |
US20090022720A1 (en) | 2007-07-20 | 2009-01-22 | Stephan Fischer | Conjugate of an antibody against CD4 and antifusogenic peptides |
US20090074766A1 (en) * | 2007-09-14 | 2009-03-19 | Ketas Thomas J | Methods of inhibiting HIV-2 infection |
CA2700354A1 (en) * | 2007-09-25 | 2009-04-02 | Trimeris, Inc. | Novel methods of synthesis for therapeutic antiviral peptides |
CN102448982B (zh) * | 2009-03-31 | 2018-04-20 | 华盛顿大学 | 用于调节靶细胞上补体调节蛋白的活性的组合物和方法 |
CN102427829A (zh) * | 2009-04-01 | 2012-04-25 | 耶达研究与发展有限公司 | Hiv-1的脂肽抑制剂 |
WO2011133948A2 (en) | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
JP5757639B2 (ja) | 2010-09-14 | 2015-07-29 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | セルピンフィンガー融合ポリペプチド |
WO2013096939A1 (en) * | 2011-12-23 | 2013-06-27 | Sri International | Selective binding compounds |
WO2013127288A1 (zh) * | 2012-02-27 | 2013-09-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 抗hiv-1多肽及其用途 |
WO2013150532A1 (en) | 2012-04-04 | 2013-10-10 | Yeda Research And Development Co. Ltd. | Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides |
WO2014041505A1 (en) * | 2012-09-13 | 2014-03-20 | Universite De Geneve | Cell penetrating peptides |
WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
CN105646717B (zh) * | 2016-01-26 | 2020-06-09 | 复旦大学 | 一种长效hiv融合抑制剂及其应用 |
EP3214093A1 (en) * | 2016-03-03 | 2017-09-06 | Fondation The Ark | Fusion respiratory syncytial virus inhibitors and use thereof |
CN106279373B (zh) * | 2016-08-17 | 2020-01-24 | 广州宏柯源生物科技有限公司 | 一种多肽起泡剂、其制备方法及应用 |
CA3031170A1 (en) | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
CA3080076A1 (en) * | 2017-08-29 | 2019-03-07 | Pharis Biotec Gmbh | Protransduzin-d - improved enhancer of gene transfer |
CN110357968B (zh) * | 2018-04-08 | 2023-08-25 | 吉林省汇融生物科技有限公司 | 抗肿瘤融合蛋白及其制法和应用 |
CN116162136A (zh) * | 2021-11-24 | 2023-05-26 | 成都奥达生物科技有限公司 | 一种抗合胞病毒膜融合抑制剂 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63258575A (ja) * | 1986-12-15 | 1988-10-26 | レプリゲン コーポレーション | 昆虫細胞中でつくられる組換えhivエンベロープタンパク |
AU626797B2 (en) * | 1987-09-08 | 1992-08-13 | Albany Medical College | Immunogenic composites capable of selectively inducing antibody production, pharmaceutical compositions employing the same and method of selectively inducing antibody production |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
IE904083A1 (en) * | 1989-11-13 | 1991-05-22 | Cambridge Biotech Corp | Diagnostic proteins to test for more than one antibody |
US5723129A (en) * | 1991-10-16 | 1998-03-03 | University Of Saskatchewan | GnRH-leukotoxin chimeras |
US5357041A (en) * | 1991-12-06 | 1994-10-18 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin |
GB9200117D0 (en) * | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
ZA934199B (en) * | 1992-06-18 | 1994-01-10 | Akzo Nv | Carrier system against gnrh |
JP4010560B2 (ja) | 1992-07-20 | 2007-11-21 | ドューク ユニバーシティー | Hiv複製を阻害する化合物 |
EP0945504A3 (en) * | 1992-12-11 | 1999-12-08 | The University Of Florida | Materials and method for control of pests |
US5464934A (en) | 1993-05-14 | 1995-11-07 | Mallinckrodt Medical, Inc. | Metal chelates as spacer compounds in biologically active peptides |
US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
FR2739621B1 (fr) * | 1995-10-05 | 1997-12-05 | Centre Nat Rech Scient | Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives |
US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
-
1998
- 1998-05-20 US US09/082,279 patent/US6258782B1/en not_active Expired - Fee Related
-
1999
- 1999-05-20 BR BR9910626-4A patent/BR9910626A/pt not_active Application Discontinuation
- 1999-05-20 NZ NZ508352A patent/NZ508352A/xx unknown
- 1999-05-20 YU YU71800A patent/YU71800A/sh unknown
- 1999-05-20 WO PCT/US1999/011219 patent/WO1999059615A1/en not_active Application Discontinuation
- 1999-05-20 HU HU0101826A patent/HUP0101826A3/hu unknown
- 1999-05-20 JP JP2000549279A patent/JP2002515449A/ja active Pending
- 1999-05-20 IL IL13970299A patent/IL139702A0/xx active IP Right Grant
- 1999-05-20 KR KR1020007012887A patent/KR100742789B1/ko not_active IP Right Cessation
- 1999-05-20 US US09/315,304 patent/US6348568B1/en not_active Expired - Fee Related
- 1999-05-20 PL PL99344342A patent/PL344342A1/xx not_active Application Discontinuation
- 1999-05-20 AU AU41949/99A patent/AU766995C/en not_active Ceased
- 1999-05-20 ID IDW20002674A patent/ID29141A/id unknown
- 1999-05-20 EP EP99925716A patent/EP1079846A4/en not_active Withdrawn
- 1999-05-20 CA CA002332338A patent/CA2332338A1/en not_active Abandoned
- 1999-05-20 RU RU2000132227/15A patent/RU2236865C2/ru not_active IP Right Cessation
- 1999-05-20 MX MXPA00011314A patent/MXPA00011314A/es not_active IP Right Cessation
- 1999-05-20 CN CNB998089362A patent/CN1205995C/zh not_active Expired - Fee Related
- 1999-05-20 TR TR2001/00163T patent/TR200100163T2/tr unknown
-
2000
- 2000-11-15 IL IL139702A patent/IL139702A/en not_active IP Right Cessation
- 2000-11-15 ZA ZA200006642A patent/ZA200006642B/en unknown
- 2000-11-17 HR HR20000789A patent/HRP20000789A2/hr not_active Application Discontinuation
- 2000-11-17 NO NO20005836A patent/NO20005836L/no not_active Application Discontinuation
-
2001
- 2001-04-13 US US09/834,784 patent/US6562787B1/en not_active Expired - Fee Related
-
2002
- 2002-02-06 HK HK02100923.0A patent/HK1039747A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IL139702A (en) | 2007-10-31 |
MXPA00011314A (es) | 2003-04-22 |
AU4194999A (en) | 1999-12-06 |
CN1310626A (zh) | 2001-08-29 |
KR100742789B1 (ko) | 2007-07-25 |
EP1079846A4 (en) | 2003-01-02 |
CA2332338A1 (en) | 1999-11-25 |
ZA200006642B (en) | 2001-05-28 |
IL139702A0 (en) | 2002-02-10 |
US6562787B1 (en) | 2003-05-13 |
NZ508352A (en) | 2004-02-27 |
PL344342A1 (en) | 2001-11-05 |
RU2236865C2 (ru) | 2004-09-27 |
HUP0101826A2 (hu) | 2001-09-28 |
WO1999059615A9 (en) | 2000-06-22 |
AU766995C (en) | 2004-12-02 |
HK1039747A1 (zh) | 2002-06-21 |
HUP0101826A3 (en) | 2005-12-28 |
WO1999059615A1 (en) | 1999-11-25 |
US6258782B1 (en) | 2001-07-10 |
CN1205995C (zh) | 2005-06-15 |
YU71800A (sh) | 2004-05-12 |
US6348568B1 (en) | 2002-02-19 |
HRP20000789A2 (en) | 2001-06-30 |
NO20005836L (no) | 2001-01-19 |
KR20010043681A (ko) | 2001-05-25 |
AU766995B2 (en) | 2003-10-30 |
ID29141A (id) | 2001-08-02 |
BR9910626A (pt) | 2006-01-03 |
JP2002515449A (ja) | 2002-05-28 |
EP1079846A1 (en) | 2001-03-07 |
NO20005836D0 (no) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200100163T2 (tr) | Güçlendirilmiş farmakokinetik özelliklere sahip hibrid polipeptidler | |
TR200200766T2 (tr) | Güçlendirilmiş farmakokinetik özelliklere sahip hibrid polipeptidler | |
TR199900267T2 (tr) | GnRH-Lökotoksin kimeralari. | |
DK1278534T3 (da) | Fremgangsmåder og sammensætninger til svækkelse af multiplikationen af HIV-1 | |
CY1113421T1 (el) | Πυρηνικα οξεα και πολυπεπτιδια υποδοχεα | |
ATE349700T1 (de) | Übergangsmetallkomplex-haltige lumineszente proteinfarben | |
DE60238541D1 (de) | Modifizierte transferrin-fusionsproteine | |
EP1461073A4 (en) | PEPTIDAGONISTS FOR PROSTATE-SPECIFIC ANTIGEN AND THEIR USE | |
TR200102423T2 (tr) | Peptid ligandları yoluyla bağlı birden fazla imünojenik bileşeni olan HBV çekirdek antijeni parçacıkları | |
MXPA04008077A (es) | Anticuerpos ant-a° y su uso. | |
CY1107881T1 (el) | Τροποποιημενα πεπτιδια ως θεραπευτικοι παραγοντες | |
DE60037450D1 (de) | Funf-helix protein | |
PT848720E (pt) | Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros | |
CY1108570T1 (el) | Gd3-μιμητικα πεπτιδια | |
ATE194168T1 (de) | Varianten in den leltin domäne von selektin | |
DE60114018D1 (de) | Von zellen präsentierte peptide | |
WO1995011975A3 (en) | Retroviral superantigens, superantigen peptides, and methods of use | |
DE69840445D1 (de) | Antigen-konstrukte, für den nachweis und die unterscheidung von antikörpern gegen hiv | |
Henry et al. | The occurrence of α-N-trimethylalanine as the N-terminal amino acid of some myosin light chains | |
Qian et al. | Neighbor‐directed histidine N (τ)–alkylation: A route to imidazolium‐containing phosphopeptide macrocycles | |
TR199901262T2 (tr) | Helicobacter pylori ve asilari. | |
ATE370160T1 (de) | Peptide mit affinität zu gp120, und ihre verwendungen | |
WO2002026783A3 (en) | Chimeric retroviral gag genes and screening assays | |
Pillai et al. | A flexible method for preparation of peptide homo‐and heterodimers functionalized with affinity probes, chelating ligands, and latent conjugating groups | |
WO2000049038A3 (de) | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung |